CF PHARMTECH (02652) announced on March 13 that the Investigational New Drug (IND) application for its self-developed inhaled powder ICF001 has been formally accepted by China's National Medical Products Administration (NMPA). ICF001 is a Category 2.1 improved new chemical drug intended for treating pulmonary arterial hypertension (PAH) and interstitial lung disease-associated pulmonary hypertension (PH-ILD). This marks the company's second improved innovative inhaled drug to receive IND acceptance following ICF004, signaling an acceleration in the harvest phase of its innovative R&D pipeline for high-end respiratory formulations.

ICF001 is an innovative inhaled powder that utilizes a prodrug mechanism to achieve long-lasting effects. Drugs in this category have established clear clinical value and demonstrated blockbuster potential in treating related rare and severe pulmonary diseases. The drug addresses significant unmet clinical needs and aims to fill a treatment gap in the domestic market. Its indications broadly cover two major pulmonary hypertension areas: WHO Group 1 PAH and Group 3 PH-ILD. Both conditions have extremely poor prognoses, creating urgent demand for better treatment options. Notably, there are currently no approved specific drugs for PH-ILD in China. The rapid advancement of ICF001 positions it to potentially become the first inhaled medication approved for PH-ILD treatment in China, addressing this market void and offering hope to hundreds of thousands of patients globally.

ICF001's innovation lies in its targeted optimization of formulation and pharmacokinetics to address clinical challenges of existing therapies. It aims to achieve two core breakthroughs while demonstrating potential for multiple indications: overcoming adherence barriers by reducing dosing frequency; optimizing pharmacokinetics to balance safety and efficacy; and showing potential for expansion into multiple indications. These differentiated advantages are based on the company's translational medicine model. If subsequent clinical studies validate improvements in tolerability and titration efficiency, the drug is expected to enhance long-term medication adherence, increase therapeutic potential, and broaden clinical accessibility.

The swift acceptance of this IND application signifies that CF PHARMTECH has entered a critical clinical research phase in developing high-barrier respiratory treatments. This milestone demonstrates the company's solid fundamentals, forward-looking strategic planning, and efficient execution in innovative drug R&D. It also lays a strong foundation for the company's deepening commitment to addressing unmet needs in the global high-value inhaled therapy market, where significant clinical expectations exist for such improved new drugs.